
CAS 1010100-07-8
:CC-885
- Urea, N-(3-chloro-4-methylphenyl)-N'-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-
- 1-(3-Chloro-4-methylphenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
CC-885
CAS :CC-885 is a modulator of cereblon (CRBN). It has potent anti-tumour activity.Formule :C22H21ClN4O4Degré de pureté :99.08% - 99.83%Couleur et forme :SolidMasse moléculaire :440.88N-(3-chloro-4-methylphenyl)-N'-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-urea
CAS :Formule :C22H21ClN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.87951-(3-Chloro-4-methylphenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea
CAS :1-(3-Chloro-4-methylphenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureaFormule :C22H21ClN4O4Degré de pureté :99%Masse moléculaire :440.88CC-885
CAS :CC-885 is a pharmacologic agent that inhibits the ubiquitin ligases, which are enzymes that catalyze the transfer of ubiquitin to proteins. CC-885 has been shown to increase the levels of ubiquitinated proteins in cells and to inhibit their degradation by the proteasome. This drug has been shown to alter translation and cellular response pathways, leading to a clinical response in patients with chronic lymphocytic leukemia (CLL). It also acts as an immunomodulatory drug for lymphocytic leukemia, inhibiting transcriptional activation of NF-κB and NFAT in T cells. CC-885 is being developed for use as a cancer therapeutic agent. The mechanism of action is not fully understood, but it may be due to its ability to inhibit DNA replication or induce apoptosis.
Formule :C22H21ClN4O4Degré de pureté :Min. 95%Masse moléculaire :440.88 g/mol





